A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1164-1174

  Embil, John M ^a   Soto, Norberto E ^b   Melnick, David A ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

antibiotic; carbapenem; diabetes mellitus; skin infection; ulcer

Indexed keywords

CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADULT; AEROBIC BACTERIUM; AGED; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAM NEGATIVE ANAEROBIC BACTERIA; HEADACHE; HOSPITAL PATIENT; HUMAN; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SKIN STRUCTURE; SKIN ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WOUND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CILASTATIN; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; THIENAMYCINS;

EID: 33748575635     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.008     Document Type: Article

References (27)

1. DiNubile M.J., and Lipsky B.A. Complicated infections of skin and skin structures: When the infection is more than skin deep. J Antimicrob Chemother 53 Suppl 2 (2004) 637-650
2. Muller L.M., Gorter K.J., Hak E., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 (2005) 281-288
3. Sader H.S., Jones R.N., Silva J.B., and SENTRY Participants Group (Latin America). Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 44 (2002) 281-288
4. Mangram A.J., Horan T.C., Pearson M.L., et al. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20 (1999) 250-278
5. Lipsky B.A., Berendt A.R., Deery H.G., et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39 (2004) 885-910
6. Cunha B.A. Antibiotic selection for diabetic foot infections: A review. J Foot Ankle Surg 39 (2000) 253-257
7. Fung H.B., Chang J.Y., and Kuczynski S. A practical guide to the treatment of complicated skin and soft tissue infections. Drugs 63 (2003) 1459-1480
8. Raghavan M., and Linden P.K. Newer treatment options for skin and soft tissue infections. Drugs 64 (2004) 1621-1642
9. Rennie R.P., Jones R.N., Mutnick A.H., and SENTRY Program Study Group (North America). Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). Diagn Microbiol Infect Dis 45 (2003) 287-293
10. Colsky A.S., Kirsner R.S., and Kerdel F.A. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol 134 (1998) 1006-1009
11. Walters D.P., Gatling W., Mullee M.A., and Hill R.D. The distribution and severity of diabetic foot disease: A com munity study with comparison to a non-diabetic group. Diabet Med 9 (1992) 354-358
12. [published correction appears in Diabetes Care. 1998;21:1032]. Yosipovitch G., Hodak E., Vardi P., et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 21 (1998) 506-509
13. Jones M.E., Karlowsky J.A., Draghi D.C., et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 22 (2003) 406-419
14. Tan J.S., Friedman N.M., Hazelton-Miller C., et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation?. Clin Infect Dis 23 (1996) 286-291
15. Muller M., Brunner M., Hollenstein U., et al. Penetration of ciprofloxacin into the interstitial space of in flamed foot lesions in non-insulindependent diabetes mellitus patients. Antimicrob Agents Chemother 43 (1999) 2056-2058
16. Zervos M. Treatment of polymicrobial intra-abdominal, pelvic, and diabetic foot infections. Compr Ther. 24 (1998) 295-301
17. Delamaire M., Maugendre D., Moreno M., et al. Impaired leucocyte functions in diabetic patients. Diabet Med 14 (1997) 29-34
18. Joshi N., Caputo G.M., Weitekamp M.R., and Karchmer A.W. Infections in patients with diabetes mellitus. N Engl J Med 341 (1999) 1906-1912
19. Pozzilli P., and Leslie R.D. Infections and diabetes: Mechanisms and prospects for prevention. Diabet Med 11 (1994) 935-941
20. Eron L.J., Lipsky B.A., Low D.E., et al. Expert panel on managing skin and soft tissue infections. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. J Antimicrob Chemother 52 Suppl 1 (2003) 3-17
21. Merrem IV (meropenem for injection) (2005), AstraZeneca Pharmaceuticals LP, Wilmington, Del
22. Primaxin IV (imipenem and cilastatin for injection) (2005), Merck & Co., Inc., Whitehouse Station, NJ
23. Fabian T.C., File T.M., Embil J.M., et al. Meropenem versus imipenemcilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: Results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 6 (2005) 269-282
24. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard. 5th ed. (2000), National Committee for Clinical Laboratory Standards, Wayne, Pa
25. NCCLS document M2-A7. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Suscep tibility Tests. Approved Standard. 7th ed. (2000), National Committee for Clinical Laboratory Standards, Wayne, Pa
26. NCCLS document M11-A5. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved Standard. 5th ed. (2001), National Committee for Clinical Laboratory Standards, Wayne, Pa
27. Graham D.R., Lucasti C., Malafaia O., et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis. 34 (2002) 1460-1468